Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 10

1.

Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.

Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N.

Br J Cancer. 2014 Oct 28;111(9):1860-9. doi: 10.1038/bjc.2014.478. Epub 2014 Sep 4.

2.

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Nick Pavlakis BI, McLean J, Marshall H, Leong S, Keena V, Penman A.

J Thorac Dis. 2013 Dec;5(6):E254-307. doi: 10.3978/j.issn.2072-1439.2013.11.28. Review. No abstract available.

3.

Biomarkers and prognostic factors for mesothelioma.

Pass HI.

Ann Cardiothorac Surg. 2012 Nov;1(4):449-56. doi: 10.3978/j.issn.2225-319X.2012.10.04. No abstract available.

4.

Mesothelin expression and survival outcomes in triple receptor negative breast cancer.

Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM.

Clin Breast Cancer. 2013 Oct;13(5):378-84. doi: 10.1016/j.clbc.2013.05.001. Epub 2013 Jun 27.

5.

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer.

Deng L, Ke X, He Z, Yang D, Gong H, Zhang Y, Jing X, Yao J, Chen J.

Int J Nanomedicine. 2012;7:5053-65. doi: 10.2147/IJN.S34801. Epub 2012 Sep 19.

6.

Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.

Røe OD, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T, Erlandsen SE, Dobra K, Sundstrøm SH.

PLoS One. 2012;7(8):e40521. doi: 10.1371/journal.pone.0040521. Epub 2012 Aug 8.

7.

Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Rusch VW, Sadelain M, Adusumilli PS.

Clin Cancer Res. 2012 May 1;18(9):2478-89. doi: 10.1158/1078-0432.CCR-11-2614. Epub 2012 Feb 27.

8.

Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

Sandeck HP, Røe OD, Kjærheim K, Willén H, Larsson E.

Diagn Pathol. 2010 Jul 6;5:47. doi: 10.1186/1746-1596-5-47.

9.

Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum.

Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, Kraus T, Brüning T, Gube M.

Biomark Insights. 2010 Jan 28;5:1-8.

10.

Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.

Røe OD, Anderssen E, Helge E, Pettersen CH, Olsen KS, Sandeck H, Haaverstad R, Lundgren S, Larsson E.

PLoS One. 2009 Aug 7;4(8):e6554. doi: 10.1371/journal.pone.0006554.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk